Skip to main content
. 2020 Nov 10;35(2):635–638. doi: 10.1038/s41375-020-01087-z

Fig. 1. Overall survival in patients with severe COVID-19 pneumonia treated with ruxolitinib plus steroid (group A) compared to controls (Group B): Kaplan Meyer curves.

Fig. 1

The day of hospitalization was considered as time 0 in the y axis. Patients were censored at the time of live discharge from the hospital. No patient was lost at follow-up.